183 related articles for article (PubMed ID: 21737619)
1. LLL12 inhibits endogenous and exogenous interleukin-6-induced STAT3 phosphorylation in human pancreatic cancer cells.
Liu A; Liu Y; Li PK; Li C; Lin J
Anticancer Res; 2011 Jun; 31(6):2029-35. PubMed ID: 21737619
[TBL] [Abstract][Full Text] [Related]
2. A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells.
Lin L; Hutzen B; Li PK; Ball S; Zuo M; DeAngelis S; Foust E; Sobo M; Friedman L; Bhasin D; Cen L; Li C; Lin J
Neoplasia; 2010 Jan; 12(1):39-50. PubMed ID: 20072652
[TBL] [Abstract][Full Text] [Related]
3. A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells.
Lin L; Benson DM; DeAngelis S; Bakan CE; Li PK; Li C; Lin J
Int J Cancer; 2012 Mar; 130(6):1459-69. PubMed ID: 21520044
[TBL] [Abstract][Full Text] [Related]
4. The small molecule, LLL12, inhibits STAT3 phosphorylation and induces apoptosis in medulloblastoma and glioblastoma cells.
Ball S; Li C; Li PK; Lin J
PLoS One; 2011 Apr; 6(4):e18820. PubMed ID: 21526200
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of STAT3 signaling blocks the anti-apoptotic activity of IL-6 in human liver cancer cells.
Liu Y; Li PK; Li C; Lin J
J Biol Chem; 2010 Aug; 285(35):27429-27439. PubMed ID: 20562100
[TBL] [Abstract][Full Text] [Related]
6. Celecoxib inhibits interleukin-6/interleukin-6 receptor-induced JAK2/STAT3 phosphorylation in human hepatocellular carcinoma cells.
Liu Y; Liu A; Li H; Li C; Lin J
Cancer Prev Res (Phila); 2011 Aug; 4(8):1296-305. PubMed ID: 21490132
[TBL] [Abstract][Full Text] [Related]
7. Two small molecule compounds, LLL12 and FLLL32, exhibit potent inhibitory activity on STAT3 in human rhabdomyosarcoma cells.
Wei CC; Ball S; Lin L; Liu A; Fuchs JR; Li PK; Li C; Lin J
Int J Oncol; 2011 Jan; 38(1):279-85. PubMed ID: 21109950
[TBL] [Abstract][Full Text] [Related]
8. JAK/STAT/SOCS-signaling pathway and colon and rectal cancer.
Slattery ML; Lundgreen A; Kadlubar SA; Bondurant KL; Wolff RK
Mol Carcinog; 2013 Feb; 52(2):155-66. PubMed ID: 22121102
[TBL] [Abstract][Full Text] [Related]
9. LLL12, a novel small inhibitor targeting STAT3 for hepatocellular carcinoma therapy.
Zuo M; Li C; Lin J; Javle M
Oncotarget; 2015 May; 6(13):10940-9. PubMed ID: 25883212
[TBL] [Abstract][Full Text] [Related]
10. IL-6, a risk factor for hepatocellular carcinoma: FLLL32 inhibits IL-6-induced STAT3 phosphorylation in human hepatocellular cancer cells.
Liu Y; Fuchs J; Li C; Lin J
Cell Cycle; 2010 Sep; 9(17):3423-7. PubMed ID: 20818158
[TBL] [Abstract][Full Text] [Related]
11. REG3A accelerates pancreatic cancer cell growth under IL-6-associated inflammatory condition: Involvement of a REG3A-JAK2/STAT3 positive feedback loop.
Liu X; Wang J; Wang H; Yin G; Liu Y; Lei X; Xiang M
Cancer Lett; 2015 Jun; 362(1):45-60. PubMed ID: 25779676
[TBL] [Abstract][Full Text] [Related]
12. Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice.
Onimoe GI; Liu A; Lin L; Wei CC; Schwartz EB; Bhasin D; Li C; Fuchs JR; Li PK; Houghton P; Termuhlen A; Gross T; Lin J
Invest New Drugs; 2012 Jun; 30(3):916-26. PubMed ID: 21340507
[TBL] [Abstract][Full Text] [Related]
13. A small molecule STAT3 inhibitor, LLL12, enhances cisplatin‑ and paclitaxel‑mediated inhibition of cell growth and migration in human ovarian cancer cells.
Zhang R; Chen X; Fu S; Xu L; Lin J
Oncol Rep; 2020 Sep; 44(3):1224-1232. PubMed ID: 32705214
[TBL] [Abstract][Full Text] [Related]
14. JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling.
Song L; Rawal B; Nemeth JA; Haura EB
Mol Cancer Ther; 2011 Mar; 10(3):481-94. PubMed ID: 21216930
[TBL] [Abstract][Full Text] [Related]
15. Discovery and evaluation of Atopaxar hydrobromide, a novel JAK1 and JAK2 inhibitor, selectively induces apoptosis of cancer cells with constitutively activated STAT3.
Sun J; Du Y; Zhang X; Wang Z; Lin Y; Song Q; Wang X; Guo J; Li S; Nan J; Yang J
Invest New Drugs; 2020 Aug; 38(4):1003-1011. PubMed ID: 31612426
[TBL] [Abstract][Full Text] [Related]
16. Dual inhibition of Janus and Src family kinases by novel indirubin derivative blocks constitutively-activated Stat3 signaling associated with apoptosis of human pancreatic cancer cells.
Nam S; Wen W; Schroeder A; Herrmann A; Yu H; Cheng X; Merz KH; Eisenbrand G; Li H; Yuan YC; Jove R
Mol Oncol; 2013 Jun; 7(3):369-78. PubMed ID: 23206899
[TBL] [Abstract][Full Text] [Related]
17. 17-hydroxy-jolkinolide B inhibits signal transducers and activators of transcription 3 signaling by covalently cross-linking Janus kinases and induces apoptosis of human cancer cells.
Wang Y; Ma X; Yan S; Shen S; Zhu H; Gu Y; Wang H; Qin G; Yu Q
Cancer Res; 2009 Sep; 69(18):7302-10. PubMed ID: 19706767
[TBL] [Abstract][Full Text] [Related]
18. Blockage of STAT3 Signaling Pathway by Morusin Induces Apoptosis and Inhibits Invasion in Human Pancreatic Tumor Cells.
Kim C; Kim JH; Oh EY; Nam D; Lee SG; Lee J; Kim SH; Shim BS; Ahn KS
Pancreas; 2016 Mar; 45(3):409-19. PubMed ID: 26646273
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-6 promotes pancreatic cancer cell migration by rapidly activating the small GTPase CDC42.
Razidlo GL; Burton KM; McNiven MA
J Biol Chem; 2018 Jul; 293(28):11143-11153. PubMed ID: 29853638
[TBL] [Abstract][Full Text] [Related]
20. Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding.
Sen B; Saigal B; Parikh N; Gallick G; Johnson FM
Cancer Res; 2009 Mar; 69(5):1958-65. PubMed ID: 19223541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]